Evaluation of a protein microarray method for immuno-typing erythrocytes in whole blood.

All donor blood samples must be tested pre-transfusion to determine the blood type of donor erythrocytes, based on the ABO typing system. Current methods of testing are well characterised, but require a number of processing steps prior to analysis. In addition, standard testing protocols require additional assays such as hepatitis C and HIV testing be performed separately.

Detection of HTLV-I and -II in Scottish blood donor samples and archive donations.

Background And Objectives: Positive samples identified during routine serological screening for HCV (hepatitis C virus), HBV (hepatitis B virus) and HIV (human immunodeficiency virus) are confirmed by nucleic acid testing in the SNBTS (Scottish National Blood Transfusion Service) PCR Reference laboratory. Serological screening for HTLV-I (human T-cell lymphotropic virus type I) and -II was implemented in Scotland in November 2002, at which time a PCR assay was not available for confirmation. Our aim was to develop a real-time PCR assay that could be used for the confirmation of samples showing HTLV-I serological positive or indeterminate reactivity and to investigate whether a serologically silent carrier status exists ('Tax' only) in the Scottish donor population.

Cutaneous leukemia inhibitory factor and its potential role in the development of skin tumors.

Leukemia inhibitory factor (LIF) is a polyfunctional cytokine with a variety and a diverse range of biological activities. However, this is a reflection of the fact that the cytokine is expressed in many different tissues, has a wide target cell range, and fulfills different functions in different tissues. The purpose of this article is to examine what is known about LIF expression in the skin and to consider whether LIF plays a role in inflammatory and hyperplastic events in the skin.

Fusion inhibitors.

The majority of current antiviral drugs target viral genome replication (eg, reverse transcriptase inhibitors) or virion maturation (eg, protease inhibitors). Although efficient, these drugs suffer from the quick appearance of drug-resistant mutants and usually do not eliminate the virus completely. Combination therapy may delay but not eliminate the emerging resistant mutants.

Microarray technology: the future of blood testing?

The increasing pace of development in molecular biological techniques during the last 10-15 years has had a direct effect on mass testing and diagnostic applications, including blood screening. Nucleic acid amplification techniques (NAT), usually based on the polymerase chain reaction (PCR), have been successfully applied to blood grouping and implemented recently in screening of blood donations for hepatitis C virus (HCV). The majority of microarray technologies involve an amplification step, yet the main benefits of this technology come from simultaneous analysis of thousands of analytes.

Evaluation of canine small intestinal permeability using the lactulose/rhamnose urinary excretion test.

The use of the lactulose and rhamnose urinary excretion test was evaluated in dogs with gastrointestinal disease. Lactulose and rhamnose urinary excretion was measured in three groups of dogs: clinically healthy dogs and dogs with gastrointestinal disease with and without coexistent panhypoproteinaemia. A significant increase in both the percentage of lactulose:percentage of rhamnose urinary excretion ratio and the percentage of lactulose excretion was demonstrated in dogs with hypoproteinaemia when compared to the other two groups.